Table 1.
Sample sociodemographic and medical characteristics
| Sociodemographic characteristics | |
|---|---|
| Female | 100.00% (88/88) |
| Age (in years, Range: 31-81) | M=58.34 (SD=10.37) |
| White/Caucasian & Non-Latina | 92.05% (81/88) |
| Hispanic/Latina | 3.41% (3/88) |
| Biracial | 1.14% (1/88) |
| Native American/Alaskan Native | 1.14% (1/88) |
| Black/African American | 0.00% (0/88) |
| Other | 2.27% (2/88) |
| Education | |
| High school diploma/some college | 15.90% (14/88) |
| Associate’s degree | 11.40% (10/88) |
| Bachelor’s degree | 33.00% (29/88) |
| Graduate/Professional degree | 39.80% (35/88) |
| Household Yearly Income | |
| Less than $30,000 | 11.40% |
| $31,000-$60,000 | 26.10% |
| $61,00-$90,000 | 19.30% |
| $91,000+ | 43.20% |
| Cancer treatment history | |
| Months from end of primary treatment (Range 1–36) | M=13.83 (SD=8.54) |
| Months prescribed endocrine therapy % who received: | M=13.11 (SD=8.29) |
| 1)Surgery | 1) 100.00% (88/88) |
| 2)Chemotherapy | 2) 34.09% (30/88) |
| 3)Targeted Therapy | 3) 10.23% (9/88) |
| 4)Radiation | 4) 68.18% (60/88) |
| Endocrine Therapy Type: | |
| 1)Aromatase Inhibitors | 1) 62.50% (55/88) |
| 2)Tamoxifen | 2) 37.50% (33/88) |
| Cancer stage | |
| 0 | 5.68% (5/88) |
| I | 71.59% (63/88) |
| II | 18.18% (16/88) |
| III | 4.55% (4/88) |